Nivolumab and Ipilimumab in Combination With Immunogenic Chemotherapy for Patients With Advanced NSCLC
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1/PHASE2
Clinical Trials Related to Nivolumab
Related studies linked through entity extraction aliases.
Nivolumab and Ipilimumab in People With Aggressive Pituitary Tumors
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
A Study to Evaluate Lucitanib in Combination With Nivolumab in Patients With a Solid Tumor
- Status
- SUSPENDED
- Phase
- PHASE1/PHASE2
Using a Targeted Cancer Vaccine (Galinpepimut-S) With Immunotherapy (Nivolumab) in Mesothelioma
- Status
- COMPLETED
- Phase
- PHASE1
A Study of Nivolumab in Combination With Ipilimumab in Participants With Advanced Hepatocellular Carcinoma
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
A Study of Nivolumab and Ipilimumab in Untreated Participants With Stage 3 Non-small Cell Lung Cancer (NSCLC) That is Unable or Not Planned to be Removed by Surgery
- Status
- COMPLETED
- Phase
- PHASE3
A Study of Neoadjuvant Chemotherapy Plus Nivolumab Versus Neoadjuvant Chemotherapy Plus Placebo, Followed by Surgical Removal and Adjuvant Treatment With Nivolumab or Placebo for Participants With Surgically Removable Early Stage Non-small Cell Lung Cancer
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
NeoVax With Nivolumab in Patients With Ovarian Cancer
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1
A Study of Nivolumab +/- Docetaxel in Patients Previously Treated With Advanced or Metastatic NSCLC
- Status
- UNKNOWN
- Phase
- PHASE2
Nivolumab Consolidation in Older (≥ 65) Patients With Primary CNS Lymphoma
- Status
- COMPLETED
- Phase
- PHASE1
BMS-986156, Ipilimumab, and Nivolumab With or Without Stereotactic Body Radiation Therapy in Treating Patients With Advanced or Metastatic Lung/Chest or Liver Cancers
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
Nivolumab in Biochemically Recurrent dMMR Prostate Cancer
- Status
- COMPLETED
- Phase
- PHASE2
Encorafenib, Cetuximab, and Nivolumab in Treating Patients With Microsatellite Stable, BRAFV600E Mutated Unresectable or Metastatic Colorectal Cancer
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1/PHASE2
A Exploratory Study of Nivolumab Monotherapy or in Combination With Nab-paclitaxel and Carboplatin in Early Stage NSCLC in China
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Adjuvant Treatment Determined By Pathological Response To Neoadjvuant Nivolumab
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Ipilimumab and Nivolumab in Combination With Radiation Therapy in Treating Patients With Stage 2-3 Non-small Lung Cancer
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1
A Study of Nivolumab, Nivolumab Plus Ipilimumab, or Investigator's Choice Chemotherapy for the Treatment of Participants With Deficient Mismatch Repair (dMMR)/Microsatellite Instability High (MSI-H) Metastatic Colorectal Cancer (mCRC)
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
A Phase II Trial of Neoadjuvant Treatment With PD-1 Inhibition (Nivolumab) With or Without IDO Inhibition (BMS-986205) and With or Without CTLA-4 Inhibition (Ipilimumab) in Resectable Stage III or IV Melanoma
- Status
- WITHDRAWN
- Phase
- PHASE2
IL13Ra2-CAR T Cells With or Without Nivolumab and Ipilimumab in Treating Patients With GBM
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1
A Phase II Study of the Interleukin-6 Receptor Inhibitor Tocilizumab in Combination With Ipilimumab and Nivolumab in Patients With Unresectable Stage III or Stage IV Melanoma
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2